Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aminosalicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminosalicylic Acid SCHEMBL29379024 | 1.00 | KDM4E (1.00) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL84166 | 0.98 | KDM4E (0.96) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL29425268 | 0.98 | KDM4E (0.96) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL11788856 | 0.96 | KDM4E (0.92) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL1047421 | 0.96 | KDM4E (0.92) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL1457932 | 0.96 | KDM4E (0.92) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL1477512 | 0.96 | KDM4E (0.92) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL31065282 | 0.96 | KDM4E (0.92) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL31598403 | 0.96 | KDM4E (0.92) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL30724149 | 0.96 | KDM4E (0.92) | KDM4ETDP1POLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 539 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-222964333-U | Production drying device for sodium p-aminosalicylate | 辽源市银鹰制药有限责任公司 | 2025-06-10 | — | — | CN | claimed |
| CN-120020209-A | In situ modified nanoparticle CO2Foam channeling sealing system and preparation method and application thereof | 中国石油化工股份有限公司 | 2025-05-20 | — | — | CN | claimed |
| CN-119468654-B | Circulating drying device for producing sodium p-aminosalicylate | 山东隆信药业有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-119552995-A | Primer composition and application thereof | 广州凯普医药科技有限公司 | 2025-03-04 | — | — | CN | claimed |
| CN-119468654-A | Circulating drying device for producing sodium p-aminosalicylate | 山东隆信药业有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119236095-A | Inflammatory microenvironment responsive cross-linked polypeptide modified liposome | 大理大学 | 2025-01-03 | — | — | CN | claimed |
| CN-116000001-B | Method for reducing TOPCon battery clamping marks and clamping points | 英利能源发展(保定)有限公司 | 2024-12-31 | — | — | CN | claimed |
| US-20240240264-A1 | RAPID MILK SAMPLE PREPARATION METHOD COMPATIBLE WITH MOLECULAR TESTS | ZOETIS SERVICES LLC | 2024-07-18 | — | — | US | claimed |
| CN-118326001-A | Dynamic monitoring and early warning system for drug resistance of new tuberculosis in Jilin region | 吉林市结核病医院 | 2024-07-12 | — | — | CN | claimed |
| CN-118241362-A | Manufacturing process of fabric capable of improving dust adhesion | 华懋（厦门）特种材料有限公司 | 2024-06-25 | — | — | CN | claimed |
| WO-2007119177-A2 | MODIFIED RELEASE FORMULATIONS AND METHODS OF TREATING INFLAMMATORY BOWEL DISEASE | AGI THERAPEUTICS RESEARCH LIMITED (US) | 2007-10-25 | — | — | WO | claimed |
| EP-1754712-A2 | Transcobalamin binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-02-21 | — | — | EP | claimed |
| US-20060223787-A1 | Modified release formulations and methods of treating inflammatory bowel disease | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2006-10-05 | — | — | US | claimed |
| US-20060166862-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2006-07-27 | — | — | US | claimed |
| CN-1162550-C | Prepn process of drug-sensitive pleurotus ostreatus culture medium | 武汉钢铁(集团)公司 | 2004-08-18 | — | — | CN | claimed |
| EP-1334114-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2003-08-13 | — | — | EP | claimed |
| CN-1398983-A | Prepn process of drug-sensitive pleurotus ostreatus culture medium | WUHAN IRON & STEEL GROUP CO (CN) | 2003-02-26 | — | — | CN | claimed |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | COLLINS DOUGLAS A (US) | 2002-10-17 | — | — | US | claimed |
| WO-2002055530-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION (US) | 2002-07-18 | — | — | WO | claimed |
| US-4734222-A | Composition and method for cleaning soft and hard contact lenses | CIBA-GEIGY CORPORATION (US) | 1988-03-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166862-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | KDM4E 4872/4885TDP1 1651/4885POLB 147/4885 |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | KDM4E 4872/4885TDP1 1651/4885POLB 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.